申请人:Novation Pharmaceuticals Inc.
公开号:US20220016071A1
公开(公告)日:2022-01-20
The present disclosure provides for compounds useful for the treatment or prevention of disorders with an etiology associated with or comprising excessive cytokine or chemokine release. The compounds are also useful for the treatment of cancer, inflammatory disorders and disorders associated with an increased stability or translation of mRNA which has an mRNA instability sequence.